Video

Targeted Therapies for Advanced MCL May Improve Outcomes as Front-line Treatment

Author(s):

Dr. Reem Karmali
Conference|ASCO Annual Meeting

Mantle cell lymphoma remains incurable, despite researchers’ best efforts. However, new treatment options show promise in the relapsed/refractory setting and may improve patient outcomes if moved to the front-line, according to Dr. Reem Karmali.

Mantle cell lymphoma (MCL) is a disease that “unfortunately still remains incurable, despite our best efforts,” according to Dr. Reem Karmali. However, due to the ever-evolving treatment landscape, new therapies are being offered to patients with relapsed and refractory MCL, including BTK inhibitors. Thanks to these targeted therapies, patients with MCL are living much longer and experiencing a better quality of life.

“BTK inhibitors like (Imbruvica [ibrutinib]) and (Calquence [acalabrutinib]) are very active with response rates from 70% to 80% in the relapsed and refractory (MCL) setting,” said Karmali. “The question is whether these agents can be moved up to the front-line setting and improve outcomes in these patients.”

At the 2019 American Society of Clinical Oncology Annual (ASCO) Meeting, she discussed the advancements being made in the treatment landscape, the use of targeted therapies to treat MCL and front-line interventions that could potentially fill the unmet needs of patients with MCL.

Related Videos
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short black hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of man with black hair.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Related Content
Image of a lymphoma cell.
November 19th 2024

Columvi Shows High Response Rates and Safety in R/R Mantle Cell Lymphoma

Spencer Feldman
Treatment with Columvi showed a manageable safety profile in heavily pre-treated patients with relapsed or refractory mantle cell lymphoma.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of radiation targeting cancer cells.
November 5th 2024

Common Prostate Cancer Radiation Questions Answered

Alex Biese
Expert answers to patients’ questions were offered as part of the CURE® Educated Patient® Prostate Cancer Summit.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of PSA test.
October 21st 2024

Rise in PSA Levels May Predict Treatment Response in Prostate Cancer

Spencer Feldman
The rate at which PSA rises after hormonal therapy for prostate cancer is a key factor in determining the effectiveness of the treatment.
Image of doctor consulting man.
October 18th 2024

Focal Therapy May Reduce Side Effects, Improve Quality of Life in Prostate Cancer

Darlene Dobkowski, MA
With approaches like high intensity focused ultrasound, patients with prostate cancer may experience lower rates of urinary incontinence and erectile dysfunction, an expert said.